Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the safety and tolerability of PRO 140, an
investigational anti-HIV drug, administered via intravenous infusion.
Study hypothesis: Single intravenous doses of PRO 140 can be safely administered to humans
and will result in measurable concentrations of the product in serum.
Phase:
Phase 1
Details
Lead Sponsor:
CytoDyn, Inc.
Treatments:
Antibodies Antibodies, Monoclonal HIV Antibodies Leronlimab PRO-140 monoclonal antibody